CR20120317A - Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a - Google Patents

Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a

Info

Publication number
CR20120317A
CR20120317A CR20120317A CR20120317A CR20120317A CR 20120317 A CR20120317 A CR 20120317A CR 20120317 A CR20120317 A CR 20120317A CR 20120317 A CR20120317 A CR 20120317A CR 20120317 A CR20120317 A CR 20120317A
Authority
CR
Costa Rica
Prior art keywords
arimidazol
heteroaromatic
derivatives
pde10a inhibitors
enzyme
Prior art date
Application number
CR20120317A
Other languages
English (en)
Inventor
Ask Pueschl
Jacob Nielsen
Jan Kehler
John Paul Kilburn
Mauro Marigo
Morten Langgaard
Original Assignee
H Lundbeck & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck & Co As filed Critical H Lundbeck & Co As
Publication of CR20120317A publication Critical patent/CR20120317A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se dirige a compuestos, que son inhibidores de la enzima PDE10A. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para la preparación de los compuestos de la fórmula I.
CR20120317A 2009-12-17 2012-06-12 Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a CR20120317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28732409P 2009-12-17 2009-12-17
DKPA200901341 2009-12-17

Publications (1)

Publication Number Publication Date
CR20120317A true CR20120317A (es) 2012-08-16

Family

ID=44246810

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120317A CR20120317A (es) 2009-12-17 2012-06-12 Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a

Country Status (34)

Country Link
US (2) US8501797B2 (es)
EP (1) EP2513105B1 (es)
JP (1) JP5698761B2 (es)
KR (1) KR101777889B1 (es)
CN (1) CN102753551B (es)
AR (1) AR079498A1 (es)
AU (1) AU2010333437B2 (es)
CA (1) CA2783727C (es)
CO (1) CO6612246A2 (es)
CR (1) CR20120317A (es)
CY (1) CY1115278T1 (es)
DK (1) DK2513105T3 (es)
DO (1) DOP2012000168A (es)
EA (1) EA021415B1 (es)
ES (1) ES2484692T3 (es)
GE (1) GEP20156242B (es)
GT (1) GT201200180A (es)
HR (1) HRP20140632T1 (es)
MA (1) MA33924B1 (es)
MX (1) MX2012007144A (es)
MY (1) MY158202A (es)
NZ (1) NZ600416A (es)
PH (1) PH12012501223A1 (es)
PL (1) PL2513105T3 (es)
PT (1) PT2513105E (es)
RS (1) RS53413B (es)
SG (1) SG181536A1 (es)
SI (1) SI2513105T1 (es)
SM (1) SMT201400114B (es)
TN (1) TN2012000287A1 (es)
TW (1) TWI481607B (es)
UA (1) UA107817C2 (es)
WO (1) WO2011072696A1 (es)
ZA (1) ZA201204418B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI481607B (zh) * 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
PH12013501254A1 (en) 2010-12-17 2016-07-29 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HRP20171859T1 (hr) 2010-12-17 2018-01-26 Reata Pharmaceuticals, Inc. Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013028590A1 (en) * 2011-08-25 2013-02-28 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
WO2013107856A1 (en) * 2012-01-20 2013-07-25 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
KR20150021120A (ko) * 2012-06-19 2015-02-27 선오비온 파마슈티컬스 인코포레이티드 헤테로아릴 화합물 및 이의 이용 방법
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
UA125302C2 (uk) * 2016-11-02 2022-02-16 Янссен Фармацевтика Нв Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
AR040847A1 (es) * 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
WO2004041258A2 (fr) 2002-10-30 2004-05-21 Neuro3D Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie
CA2530114A1 (en) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
KR20060030483A (ko) 2003-06-30 2006-04-10 알타나 파마 아게 Ｐｄｅ10 억제제로서 피롤로디히드로이소퀴놀린
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
JP2007523152A (ja) 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
JP2009535394A (ja) * 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8492394B2 (en) * 2006-07-10 2013-07-23 H. Lundbeck A/S (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物

Also Published As

Publication number Publication date
DK2513105T3 (da) 2014-07-14
NZ600416A (en) 2013-08-30
CN102753551A (zh) 2012-10-24
EP2513105A1 (en) 2012-10-24
PH12012501223A1 (en) 2022-10-03
ES2484692T3 (es) 2014-08-12
SMT201400114B (it) 2014-11-10
JP5698761B2 (ja) 2015-04-08
AR079498A1 (es) 2012-02-01
US20130289038A1 (en) 2013-10-31
SI2513105T1 (sl) 2014-11-28
HRP20140632T1 (hr) 2014-09-26
EA021415B1 (ru) 2015-06-30
CA2783727A1 (en) 2011-06-23
PL2513105T3 (pl) 2014-09-30
US8501797B2 (en) 2013-08-06
DOP2012000168A (es) 2012-11-30
KR101777889B1 (ko) 2017-09-12
ZA201204418B (en) 2013-08-28
CO6612246A2 (es) 2013-02-01
TWI481607B (zh) 2015-04-21
RS53413B (sr) 2014-12-31
MX2012007144A (es) 2012-07-03
KR20120123276A (ko) 2012-11-08
GEP20156242B (en) 2015-02-10
US20120302548A1 (en) 2012-11-29
TW201127831A (en) 2011-08-16
AU2010333437A1 (en) 2012-06-21
SG181536A1 (en) 2012-07-30
CA2783727C (en) 2018-02-20
HK1177739A1 (en) 2013-08-30
MY158202A (en) 2016-09-15
CY1115278T1 (el) 2017-01-04
EA201290518A1 (ru) 2013-01-30
TN2012000287A1 (en) 2013-12-12
JP2013514285A (ja) 2013-04-25
CN102753551B (zh) 2014-10-22
EP2513105B1 (en) 2014-05-14
AU2010333437B2 (en) 2016-09-01
PT2513105E (pt) 2014-07-31
WO2011072696A1 (en) 2011-06-23
UA107817C2 (en) 2015-02-25
US8927738B2 (en) 2015-01-06
GT201200180A (es) 2015-01-16
MA33924B1 (fr) 2013-01-02

Similar Documents

Publication Publication Date Title
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
CR20120319A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
CR20120318A (es) Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a
DOP2012000168A (es) Derivados de 2-arimidazol heteroaromaticos como inhibidores de enzima pde10a
CO6321263A2 (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
ECSP12011793A (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene
ECSP11011526A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
UY32660A (es) Derivados aminobutricos sustituidos como inhibidores de neprilisina
UY32662A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina
UY32490A (es) Inhibidores de beta-secretasa
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
MY165087A (en) Neprilysin inhibitors
GEP20146202B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
UY33075A (es) Derivados de ciclohexano y usos de los mismos
CR20130226A (es) Derivados de imidazol como inhibidores de la enzima pde10a
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
EA201391524A1 (ru) Производные гликозида и их применение
UY33348A (es) Compuestos de furopiridina y usos de los mismos
PE20141021A1 (es) DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO
DOP2013000108A (es) Derivados de imidazol como inhibidores de la enzima pde10a
TN2011000573A1 (en) Aryl pyridine as aldosterone synthase inhibitors